TMO Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.…
Industry Peers
Diagnostics & ResearchKey Statistics
About Thermo Fisher Scientific (NYSE: TMO)
›
Thermo Fisher Scientific (NYSE: TMO) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 125,000 employees.
The shares were at 688.75 USD on 19 November 2026, up 19.2% over 52 weeks. Its 52-week range is 435.27 USD to 727.56 USD: the price is 5.3% below the high and 58.2% above the low.
At a market capitalisation of 255.19B USD, it trades at 36.3 times trailing earnings and 24.8 times forward earnings. The median trailing P/E of its 18 largest Diagnostics & Research peers is 34.9, so TMO is valued in line with them. It pays a dividend yielding 0.27% (it pays out 10% of its earnings), against a median of 0.77% among the dividend payers in that peer group.
Thermo Fisher Scientific reports return on equity of 12.6%, an operating margin of 19.1% and revenue up 9.1% year over year.
Its debt exceeds its cash by 35.31B USD, a debt-to-equity ratio of 0.74. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 25 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 756.52 USD is 9.8% above the current price. The next earnings report is expected on 28 January 2027.